Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or planned future fundraising through debt or equity in the provided transcript. The management discusses ongoing capital expenditures, such as the capitalization of the Dahej plant and upcoming Sotanala plant expansion, but does not mention raising funds for these projects through new debt or equity issuance. Efforts focus more on operational improvements, product launches, and backward integration rather than fundraising. The CFO and management highlight stable financial performance and margin improvements, indicating no immediate requirement for e

Any current/future capex/capital investment/strategic investment?

The Dahej plant Phase 1 technical unit has been completed and started production recently. A new facility is being set up at Sotanala, Rajasthan, including both formulation and technical plants. The formulation unit at Sotanala is targeted to start by the next kharif season. The technical plant Phase 1 at Sotanala is expected to commence by the end of the next fiscal. Ongoing continuous efforts in backward integration to reduce import dependency through indigenous production. Strategic investments in R&D, including collaboration with OAT Agrio for new product development with product launches

Future growth expectations in sales/revenue/volumes?

Targeting double-digit growth in premium products with a focus on crops like rice, corn, soybean, wheat, sugarcane, horticulture, and pulses. Total revenue growth expected around 10% plus/minus annually, with a healthy B2C segment driving growth. B2B and export businesses are also expected to grow with new active ingredients and product launches. New product Altair aims to reach maturity volumes treating 0.5 million acres, targeting approximately INR70 crores revenue. Strategic product launches (e.g., Altair, SPARCLE) and collaborations (e.g., Corteva) are expected to contribute positi

Future growth expectations in earnings/operating earnings/profits/EPS?

The company targets a continued double-digit growth in premium products, contributing to revenue growth. Overall revenue growth guidance is maintained at around 10% plus/minus. EBITDA margin improvement target is about 100 basis points over the next 2-3 years. The company plans to sustain or improve the current EBITDA margin, which already improved by 120 basis points YoY in Q1 FY '26. Profitability is expected to be supported by premiumization of the product portfolio and "tail cutting" of low-return generics. New product launches and expansion in key crop segments will support growth. The B2

Current/ Expected Orderbook/ Pending Orders?

The company has signed various contracts with at least 2 companies or more (Page 14). There is strong full demand across the country, with every state asking for more raw materials (Page 14). The outlook indicates preparation and readiness for the kharif season and rabi season, with key raw materials already bought for upcoming quarters (Page 14). The company is continuously working on controlling imports and increasing backward integration to reduce dependency, maintaining an import level around INR500-600 crores annually (Page 14). No specific numeric value of current orderbook or pending or

IN US

Sale is live|00:00:00left today

Insecticides India LtdQ2 FY25Fertilizers & Agrochemicals

Insecticides India Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹669P/E: 14.8Market Cap: ₹2.1K CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 4

→Targeting double-digit growth in premium products with a focus on crops like rice, corn, soybean, wheat, sugarcane, horticulture, and pulses.
→Total revenue growth expected around 10% plus/minus annually, with a healthy B2C segment driving growth.
→B2B and export businesses are also expected to grow with new active ingredients and product launches.
→New product Altair aims to reach maturity volumes treating 0.5 million acres, targeting approximately INR70 crores revenue.
→Strategic product launches (e.g., Altair, SPARCLE) and collaborations (e.g., Corteva) are expected to contribute positively.
→Continuous expansion through farmer connect, premium product portfolio, and backward integration efforts.
→Full preparedness for the kharif and rabi seasons with anticipations of robust demand across states.
→Total sales growth is expected to sustain at low single-digit to mid-single-digit levels with margin improvement.

Margin guidance

Category 3

→The company targets a continued double-digit growth in premium products, contributing to revenue growth.
→Overall revenue growth guidance is maintained at around 10% plus/minus.
→EBITDA margin improvement target is about 100 basis points over the next 2-3 years.
→The company plans to sustain or improve the current EBITDA margin, which already improved by 120 basis points YoY in Q1 FY '26.
→Profitability is expected to be supported by premiumization of the product portfolio and "tail cutting" of low-return generics.
→New product launches and expansion in key crop segments will support growth.
→The B2B segment and export business are also expected to grow alongside B2C.
→The company anticipates replacing sales returns through strong demand for new products in rice herbicides, insecticides, and fungicides.
→Capex completion (Dahej, Sotanala) will aid further expansion and technical capabilities, supporting growth from FY '27 onward.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no explicit mention of any current or planned future fundraising through debt or equity in the provided transcript.
→The management discusses ongoing capital expenditures, such as the capitalization of the Dahej plant and upcoming Sotanala plant expansion, but does not mention raising funds for these projects through new debt or equity issuance.
→Efforts focus more on operational improvements, product launches, and backward integration rather than fundraising.
→The CFO and management highlight stable financial performance and margin improvements, indicating no immediate requirement for external capital.

Order book

→The company has signed various contracts with at least 2 companies or more (Page 14).
→There is strong full demand across the country, with every state asking for more raw materials (Page 14).
→The outlook indicates preparation and readiness for the kharif season and rabi season, with key raw materials already bought for upcoming quarters (Page 14).
→The company is continuously working on controlling imports and increasing backward integration to reduce dependency, maintaining an import level around INR500-600 crores annually (Page 14).
→No specific numeric value of current orderbook or pending orders was disclosed, but overall demand and contract activity suggest a healthy order pipeline (Page 14).

Capex plans

Yes

→The Dahej plant Phase 1 technical unit has been completed and started production recently.
→A new facility is being set up at Sotanala, Rajasthan, including both formulation and technical plants.
→The formulation unit at Sotanala is targeted to start by the next kharif season.
→The technical plant Phase 1 at Sotanala is expected to commence by the end of the next fiscal.
→Ongoing continuous efforts in backward integration to reduce import dependency through indigenous production.
→Strategic investments in R&D, including collaboration with OAT Agrio for new product development with product launches expected from 2025-26 onwards.
→Focus on expanding product pipeline, distribution reach, and digital engagement with farmers as part of strategic growth initiatives.

How does Insecticides India Ltd rank vs peers in Fertilizers & Agrochemicals?

Pro feature

1Insecticides India Ltd

Rev 4Mar 3

See full Fertilizers & Agrochemicals sector rankings

Want more stocks like Insecticides India Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio